$100 off your first order. Code: WELCOME100

100% online
FDA regulated pharmacies
Free expedited delivery
No hidden fees
Unlimited 24/7 support
100,000+ members
100% online
FDA regulated pharmacies
Free expedited delivery
No hidden fees
Unlimited 24/7 support
100,000+ members

PT-141 Dosage: How Much, How Often, and Nasal Spray vs Injection

The PT-141 dosage on the Vyleesi label is 1.75 mg, injected under the skin as needed at least 45 minutes before sexual activity, for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).1 HSDD is low sexual desire that causes distress or interpersonal difficulty. Acquired HSDD develops in someone who previously had no problems with sexual desire, and generalized HSDD occurs regardless of the type of stimulation, situation or partner.

PT-141 is another name for bremelanotide, and Vyleesi is a brand-name bremelanotide injection approved by the Food and Drug Administration (FDA) for these women.2,1 It is not indicated for men or for postmenopausal women.1

Bremelanotide improved desire scores and lowered distress over low desire more than a placebo did, in two 24-week trials in premenopausal women with HSDD.3

Compounded drugs, compounded PT-141 included, are not FDA-approved.4 Telezen MD offers compounded PT-141 as an injection or a nasal spray.

PT-141 Dosage: How Much, When and How Often

Vyleesi is used only when needed: one 1.75 mg injection under the skin of the abdomen or thigh, at least 45 minutes before sex, for premenopausal women with acquired, generalized HSDD.1 No second dose is taken within 24 hours: a second dose that soon has no established benefit, and doses close together may add to the effect on blood pressure.1

  • How often: most patients used Vyleesi two to three times a month, and no more than once a week.1
  • Monthly limit: the label does not recommend more than 8 doses a month, and few patients in the phase 3 program received more than 8.1
  • Why the limit: more frequent dosing raises the risk of focal hyperpigmentation and lengthens the time each month when blood pressure is raised.1 Focal hyperpigmentation is darkening of the skin on parts of the body such as the face, gums and breasts.
  • When to stop: the label says to stop after 8 weeks if there is no improvement in symptoms.1

MedlinePlus advises using bremelanotide injection exactly as directed, never more or less of it and never more often than prescribed.5

Does PT-141 Work at the Label Dose?

Yes, for the women it was tested in: in two trials, bremelanotide raised sexual desire and reduced distress about low desire more than a placebo.3

  • The RECONNECT trials were two identical 24-week trials that gave premenopausal women with hypoactive sexual desire disorder (HSDD) 1.75 mg of bremelanotide under the skin as needed, or a placebo.3
  • The results: from the start to the end of the study, desire scores rose and distress scores fell more with bremelanotide than with placebo, among the 1,202 women analysed for efficacy.3 The difference was statistically significant in both trials, and of similar size in each.1
  • Compounded PT-141: these trials did not test Telezen MD’s compounded PT-141, so they do not show whether it works, and their results should not be assumed to carry over to it, or to groups the trials did not study. Whether it helps you is something to judge with your provider: ask how you will tell, and when you would stop.

Results vary from person to person, and these group results should not be read as a forecast of what one woman will notice.

What PT-141, Bremelanotide and Vyleesi Are

PT-141 and bremelanotide are two names for the same substance, and Vyleesi is a brand-name injection of it, given under the skin with an autoinjector.2,1

How to Take a PT-141 Injection

Vyleesi is a prefilled autoinjector pen that patients use themselves, injecting into the skin of the stomach area or the front of the thigh.1,5 The medicine goes in subcutaneously, which means under the skin.

The steps for the Vyleesi pen:

  • Before the first injection, read the manufacturer’s instructions and ask your provider or pharmacist to show you how to inject.5
  • Check the medicine for particles and discoloration before each use.1
  • Stay out of the 2-inch area around the belly button.5
  • Do not inject into skin that is irritated, sore, bruised, red, hard or scarred, or through clothing.5
  • Choose a different site for each injection.5

These steps are for the Vyleesi pen; if you are prescribed PT-141 at Telezen MD, the instructions for using it come with your care.

What a PT-141 Injection Feels Like

Pain, redness, bruising, itching, numbness or tingling where the medicine was injected are among the side effects of bremelanotide injection, MedlinePlus says.5 In the label’s trials in premenopausal women with HSDD, injection site reactions were more common with Vyleesi than with placebo.1

PT-141 Dosage for Women

For women, the Vyleesi label sets a 1.75 mg dose, used as needed, for premenopausal women with acquired, generalized HSDD.1 The label excludes HSDD caused by another medical or psychiatric condition, by relationship problems, or by a medicine or drug.1

Vyleesi is not indicated for HSDD in postmenopausal women, and it is not indicated to enhance sexual performance.1 Women in its main trials were aged 19 years to 56 years.1

In an integrated analysis of the RECONNECT trials, the improvements in desire and distress held across groups by age, weight, body mass index and starting testosterone level, with few exceptions.6

Is There a PT-141 Dosage for Men?

Vyleesi is not indicated for HSDD in men, its label says, and MedlinePlus says bremelanotide injection should not be used for the treatment of HSDD in men.1,5

  • A trial in 342 married men aged 28 years to 59 years enrolled men whose erectile dysfunction had not responded to sildenafil.7 They used bremelanotide as a nasal spray, or a placebo spray, 45 minutes to 2 hours before sexual stimulation.7
  • The results: more men on bremelanotide than on placebo had a positive clinical result, and they reported greater satisfaction with intercourse.7 Drug-related side effects were also more common with bremelanotide.7 The authors wrote that further studies with different doses and regimens are needed before final conclusions on its effect in erectile dysfunction.7

Given all that, for men at Telezen MD a licensed provider reviews your health history first and guides any dose. If, knowing this, you would still like a provider to consider PT-141 for you, the PT-141 page has a Get Started (Men) button.

PT-141 Nasal Spray vs Injection

The injection is the only form on the Vyleesi label; early studies in women used a nasal spray, and the developers moved to the injection because the amount reaching the blood from the nose varied.1,8

In the FDA’s review, the same nasal dose gave blood levels that varied moderately to widely.8 The spray also got less into the blood for its size: a 20 mg nasal dose, chosen to be above the 1.75 mg injected treatment dose, reached only about 2.5 times the injection’s blood level, although the dose itself was far larger.8

In a placebo-controlled study in the FDA’s review of Vyleesi, 24 healthy men and women took a single nasal dose with alcohol.8 Nasal congestion was one of the most common side effects among all subjects.8

For someone choosing, the label dose and the RECONNECT trials’ results are both for the injection.1,3 Ask your provider which form suits you; at Telezen MD, a licensed provider reviews the form you pick at intake.

Is There a Set PT-141 Nasal Spray Dosage?

There is no PT-141 nasal spray dosage on the Vyleesi label, whose only dosage form is an injection.1 So for the spray, and for Telezen MD’s compounded injection, your dose comes from a licensed provider, not from the Vyleesi label: the provider reviews your health history at intake and guides your dose.

How Long Does PT-141 Last, and How Soon Does It Work?

How long PT-141 lasts after each dose is unknown, the Vyleesi label says, and the label sets each dose at least 45 minutes before sexual activity.1 After an injection, bremelanotide reaches its highest level in the blood in a median of about 1.0 hour.1 The best time to take it has not been fully worked out.1 Patients may choose their own timing from how long they feel the effect on desire lasts and from side effects such as nausea.1

Is PT-141 FDA-Approved?

Vyleesi, a brand-name bremelanotide injection, is FDA-approved for premenopausal women with acquired, generalized HSDD; compounded PT-141 is not FDA-approved.1,4 The FDA first approved Vyleesi in 2019.1

Compounding is generally a practice in which a licensed pharmacist or physician combines, mixes or alters the ingredients of a drug to create a medication tailored to one patient. The FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.4

Section 503A is the part of federal law under which state-licensed physicians and pharmacists compound.9 In 2020, the FDA warned one compounding firm that its products compounded with bremelanotide (PT-141) did not qualify for that section’s exemptions.10

PT-141 at Telezen MD

Telezen MD provides compounded PT-141 in two forms, an injection and a nasal spray. You choose your preferred form at intake, and a licensed provider reviews it.

  • How to start: complete a short online intake, and a licensed medical provider reviews your health history.
  • Your dose: a licensed provider guides your dose, and the instructions for using your PT-141 are part of your care.
  • Delivery: if you are approved, a partner pharmacy prepares your prescription and ships it to your home.
  • Cost: the PT-141 page lists plans starting at $148 per month; see the plan details there.

The page has separate Get Started buttons for men and for women.

PT-141 Side Effects, Risks and Who Should Not Take It

Nausea, flushing, headache and injection site reactions were bremelanotide’s most common side effects in the double-blind phase 3 trials, all more frequent than on placebo.11 The label rules Vyleesi out for people with uncontrolled high blood pressure or known cardiovascular disease.1 Each dose also briefly raises blood pressure, and nausea, focal hyperpigmentation and larger rises in blood pressure are more likely with higher doses.1

See also the important safety information.

Common Side Effects

Nausea was the most common side effect in Vyleesi’s phase 3 trials.1

The label’s double-blind trials in premenopausal women with HSDD gave Vyleesi to 627 women and a placebo to 620; the side effects below were reported by at least 2% of patients.1

  • Nausea: 40.0 of every hundred women on Vyleesi against 1.3 on placebo.1
  • Flushing: 20.3 of every hundred women on Vyleesi against 0.3 on placebo.1
  • Injection site reactions, such as pain, redness, bruising, itching, numbness or tingling: 13.2 of every hundred women on Vyleesi against 8.4 on placebo.1
  • Headache: 11.3 of every hundred women on Vyleesi against 1.9 on placebo.1

Nausea needed anti-nausea medicine in 13% of patients on Vyleesi and led 8% to leave the trials early.1 For most patients, nausea improves with the second dose, the next time they use Vyleesi.1

Blood Pressure and Heart Rate

In clinical studies of Vyleesi, the largest rises were 6 mmHg in systolic and 3 mmHg in diastolic blood pressure, peaking 2 hours to 4 hours after the dose.1 Heart rate fell by up to 5 beats per minute, and both usually returned to their starting level within 12 hours.1

Skin Darkening

Focal hyperpigmentation, including on the face, gums and breasts, was reported in 1% of patients who took up to 8 doses a month, and in no one on placebo.1

The label directs as-needed use; in another study, patients instead took Vyleesi every day, and 38% developed focal hyperpigmentation after 8 days.1 Among those who kept taking it daily for 8 more days, an additional 14% developed new patches.1 Patients with dark skin were more likely to develop it.1

After Vyleesi was stopped, clearing of the darkening was not confirmed in every patient, and the label says to consider stopping Vyleesi if it develops.1 MedlinePlus advises talking to your provider about any changes to your skin while using bremelanotide injection.5

Who Should Not Take PT-141

  • High blood pressure that is not under control, or known cardiovascular disease: the label says Vyleesi must not be used.1
  • High cardiovascular risk: Vyleesi is not recommended, and blood pressure should be well controlled before starting and during treatment.1
  • Pregnancy: women should use effective contraception while taking Vyleesi and stop it if pregnancy is suspected.1
  • Children: its safety and effectiveness have not been established in pediatric patients.1

Medicines That Interact With PT-141

  • Oral medicines: Vyleesi may slow stomach emptying and reduce how well oral medicines are absorbed.1 The label says to avoid it with oral drugs that work only once they reach a certain level in the blood, such as antibiotics.1
  • Quick-acting pain relief: if a medicine taken by mouth alongside Vyleesi for a quick effect, such as the pain reliever indomethacin, starts working later than it should, the label says patients should consider stopping Vyleesi.1
  • Oral naltrexone: Vyleesi may sharply lower the level of naltrexone taken by mouth for alcohol or opioid addiction, so the two should not be used together.1

Tell your provider about every medicine you take before you start.

How PT-141 Works

The way bremelanotide improves HSDD in women is unknown, the Vyleesi label says.1 Bremelanotide acts on several melanocortin receptors, and at treatment doses two of them matter most.1

One of the two is found on nerve cells of the central nervous system.8 A review in the journal Drugs says this receptor is thought to be important for sexual function.12

The other sits on melanocytes, and activating it leads to the production of melanin.8 The FDA’s review of Vyleesi names darker pigmentation as the expected effect, and it was seen in people.8

Alternatives to PT-141

Flibanserin (Addyi), a tablet taken once daily at bedtime, is another medicine labeled for acquired, generalized HSDD in women.13 Its label dose is 100 mg, it is labeled for women under 65 years, and it is not indicated in men.13 Drinking alcohol close in time to Addyi raises the risk of severely low blood pressure and fainting.13

A review of 8 randomized trials in 7906 women with HSDD found that, in premenopausal women, flibanserin 100 mg raised the number of satisfying sexual events per month more than a placebo.14 Dizziness, fatigue, nausea, sleepiness and insomnia were more likely with flibanserin, though mild.14 Its authors concluded that the benefits may be overshadowed by the higher chance of side effects.14

What to Keep in Mind About the Research

The RECONNECT trials tested bremelanotide in premenopausal women with HSDD and were funded by Palatin Technologies and AMAG Pharmaceuticals.3

  • Who took part: most participants were white (85.6%) and from sites in the United States (96.6%), with an average age of 39 years.3
  • Longer use: both trials added an uncontrolled, 52-week open-label extension, in which 684 patients took Vyleesi.1

Questions to Ask Your Provider Before Starting PT-141

  • Is PT-141 a fit for my symptoms and my health history?
  • Is the injection or the nasal spray the better form for me, and why?
  • How will my dose be set, and how far before sexual activity should I take it?
  • What should I do if I feel nausea, or notice dark patches on my skin?
  • Do my blood pressure, my heart health or my other medicines change whether I should take it?
  • How will we judge whether it is helping, and when would we stop?

When you are ready, start with the short online intake on the PT-141 page.

Frequently Asked Questions

What is the PT-141 dosage?

The Vyleesi label sets a single dose injected under the skin of the abdomen or thigh, used as needed ahead of sexual activity, for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Doses are at least a full day apart. At Telezen MD, a licensed provider guides the dose of PT-141.

How often can you take PT-141?

The Vyleesi label allows no more than one dose within a full day and does not recommend more than eight doses a month. Most patients used it two to three times a month, and no more than once a week.

Does PT-141 work?

Yes, for premenopausal women with hypoactive sexual desire disorder: in two trials, bremelanotide raised sexual desire and eased distress about low desire more than a placebo did. Telezen MD’s PT-141 is compounded, and these results should not be assumed to carry over to it. Vyleesi is not indicated for men or for postmenopausal women.

How long does PT-141 last?

The Vyleesi label says the duration of the effect after each dose is unknown. Patients may time their dose by how long they feel the effect lasts and by any side effects, such as nausea.

Does a PT-141 injection hurt?

It can: injection site reactions, including pain, redness, bruising and itching, were more common with Vyleesi than with placebo in the label’s trials.

Is there a PT-141 nasal spray dosage?

There is none on the Vyleesi label, whose only dosage form is an injection.

Is there a PT-141 dosage for men?

Vyleesi is not indicated for HSDD in men, its label says. In men whose erectile dysfunction had not responded to sildenafil, bremelanotide was tested as a nasal spray.

Is PT-141 FDA-approved?

Vyleesi, a brand-name bremelanotide injection, is FDA-approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Compounded drugs, compounded PT-141 included, are not FDA-approved.

Sources

  1. VYLEESI (bremelanotide injection), for subcutaneous use: highlights of prescribing information, U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210557s002lbl.pdf
  2. Peptides for male sexual dysfunction: a systematic review of emerging evidence., The journal of sexual medicine, 2026. https://pubmed.ncbi.nlm.nih.gov/43002584/
  3. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials., Obstetrics and gynecology, 2019. https://pubmed.ncbi.nlm.nih.gov/31599840/
  4. Compounding and the FDA: Questions and Answers | FDA, www.fda.gov. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  5. Bremelanotide Injection: MedlinePlus Drug Information, MedlinePlus. https://medlineplus.gov/druginfo/meds/a619054.html
  6. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide., Journal of women’s health (2002), 2022. https://pubmed.ncbi.nlm.nih.gov/35230162/
  7. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study., The Journal of urology, 2008. https://pubmed.ncbi.nlm.nih.gov/18206919/
  8. Center for Drug Evaluation and Research, Application Number 210557Orig1s000, Multi-Discipline Review (Vyleesi, bremelanotide), U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf
  9. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act | FDA, U.S. Food and Drug Administration, 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  10. Tailor Made Compounding LLC – 594743 – 04/01/2020 | FDA, U.S. Food and Drug Administration, 2020. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020
  11. Safety Profile of Bremelanotide Across the Clinical Development Program., Journal of women’s health (2002), 2022. https://pubmed.ncbi.nlm.nih.gov/35147466/
  12. Bremelanotide: First Approval., Drugs, 2019. https://pubmed.ncbi.nlm.nih.gov/31429064/
  13. ADDYI (flibanserin) tablets, for oral use: highlights of prescribing information, U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022526s013lbl.pdf
  14. Role of flibanserin in managing hypoactive sexual desire disorder in women: A systematic review and meta-analysis., Medicine, 2024. https://pubmed.ncbi.nlm.nih.gov/38905407/
Disclaimer

This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Telezen MD services are available only to patients who qualify following an online medical evaluation with a licensed healthcare provider. Results vary by individual. Compounded medications prescribed through Telezen MD are compounded by 503A FDA-regulated pharmacies. Compounded medications are not reviewed or approved by the FDA for safety or efficacy. Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any new medical treatment. If you experience any adverse effects, contact your provider immediately.